Press Room

RDD 2022

Start
Monday, April 25, 2022 - 00:00
End
Thursday, June 30, 2022 - 00:00
Location: Florida, USA
Booth Number: Table 11
Hovione present at RDD 2022 | The specialist integrated CDMO

If you would like to find more about Hovione's full range of inhalation development servicesparticle engineering and development by design schedule a meeting with us.

 

Our experts are available to listen and understand your projects. Together we can speed up your Inhalation drug development, with less regulatory hurdles, less time, and less costs.

  

 
Drug Product Facility in Portugal | Hovione

Hovione Inhalation Development Virtual Tour (click on the image to watch video)

Meet Eunice Costa, Hovione’s group leader for Inhalation Development and visit the site where all the team sits together.

 

 

Schedule a meeting button | Hovione

 

 

 

 

Find more about Respiratory Drug Delivery 2022 (RDD 2022)

 

 

 

 

Also in the Press Room

See All

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026